Extralevator Versus Standard Abdominoperineal Resection For Rectal Adenocarcinoma
Rectal Adenocarcinoma
About this trial
This is an interventional treatment trial for Rectal Adenocarcinoma focused on measuring rectal adenocarcinoma, Standard APR, Extralevator APR
Eligibility Criteria
Inclusion Criteria:
- Resectable, histologically proven primary adenocarcinoma of the low rectum with internal and/or external sphincter muscle involvement. Staged as follows prior to neoadjuvant chemoradiation:
- Stage T3 or T4 at MRI
- N0-2 at MRI
- M0 at CT scan
- Patient must undergo long term neoadjuvant chemoradiation: 20 fractions of radiation over ≥5 weeks: total of 50-60 Gy, and chemotherapeutic agents
Exclusion Criteria:
- Squamous cell carcinoma
- Adenocarcinoma Stage T1-2, any N
- T4 with one of the following:
with pelvic side wall involvement requiring sacrectomy requiring prostatectomy (partial or total) Distant metastasis (M1) Unresectable primary rectal cancer or Inability to complete R0 resection. Recurrent rectal cancer Previous pelvic malignancy Inability to sign informed consent Pregnancy
Sites / Locations
- State University Hospital Medical CenterRecruiting
- Stony Broook University Medical CenterRecruiting
- Stony Brook University Medical CenterRecruiting
- Stony Brook University Medical CenterRecruiting
Arms of the Study
Arm 1
Arm 2
Experimental
Active Comparator
extralevator APR
standard APR
This is a modified and more extensive procedure that is used to remove the levator muscle en bloc with the anal canal and the mesorectum, creating a more "cylindrical" specimen, so that the amount of tissue removed around the tumor will be larger, thereby reducing the probability that the CRM will be positive.
conventional abdominoperineal resection (APR)